Growth Hormone vs Peptides: What Actually Works

Most people hear "growth hormone" and "peptides" and assume they are the same thing, or at least that they work the same way, but they don't operate through the same mechanisms and they don't hit the same parts of the hormonal chain, and because of that they produce different outcomes at different price points, so understanding the full pathway from brain to bloodstream is what separates someone who is actually optimizing their physiology from someone who is just injecting things and hoping.

So if you want to understand how this works, you need to trace the whole chain from the top, starting with your hypothalamus, which sits deep in the brain and releases something called growth hormone releasing hormone, or GHRH, which travels a very short distance to your pituitary gland. The pituitary then pulses out growth hormone into your bloodstream, primarily during deep sleep and after exercise. That growth hormone travels to your liver, which converts it into IGF-1, and IGF-1 is what actually drives most of the downstream effects people care about, things like tissue repair, muscle protein synthesis, fat metabolism, and collagen turnover. But the system has a built in brake. When IGF-1 levels rise high enough, it feeds back to the hypothalamus and pituitary and tells them to slow down production. This is the feedback loop that keeps everything in balance.

That feedback loop is the whole reason these two categories, secretagogues and direct growth hormone, behave so differently in your body.

You have your growth hormone secretagogues, which include Tesamorelin, CJC-1295, and Sermorelin, and what makes these compounds distinct is that they don't inject growth hormone into the picture at all, because what they actually do is act upstream at the level of the brain, nudging the hypothalamus or pituitary to release more of your own growth hormone in a pulsatile pattern that mirrors what your body does naturally.

The way to picture it is that your pituitary is a faucet, and over time, especially as you age, the handle gets stiffer and harder to turn, and what secretagogues do is not replace the faucet but loosen the handle so the water that comes out is still entirely your own.

Tesamorelin is the most well studied of the three and is actually FDA approved, though specifically for HIV associated lipodystrophy. In clinical trials published in the Journal of Clinical Endocrinology and Metabolism, tesamorelin increased IGF-1 levels by roughly 80 to 100 percent from baseline in adults, which is a substantial rise. It also reduced visceral adipose tissue by about 15 percent over 26 weeks, which is meaningful because visceral fat is the metabolically dangerous kind that wraps around your organs. CJC-1295, especially when paired with a compound called ipamorelin, works through a similar GHRH mimicry pathway, though the clinical data behind it is thinner and mostly comes from smaller studies and clinical practice observations rather than large randomized trials. Sermorelin is the oldest of the group and was actually FDA approved in the 1990s for diagnosing and treating growth hormone deficiency in children, but it has a very short half life, which means it gets broken down quickly and doesn't produce as strong a pulse of growth hormone compared to the other two.

The order of these three compounds tracks closely with both their price and the magnitude of growth hormone response you can expect, with Tesamorelin at the top, CJC-1295 in the middle, and Sermorelin at the bottom, so the cheapest option is also the one that sends the weakest signal to your pituitary and generates the smallest overall response.

Because all three of these compounds work through the brain, they respect your body's natural feedback loop. When IGF-1 rises, the hypothalamus still recognizes that signal and modulates production accordingly, which means you are not overriding the system but amplifying one that is already running, and that distinction matters because working with the existing architecture instead of bypassing it is how we optimize natural levels of growth hormone production in the body.

Now here is where direct growth hormone, meaning exogenous recombinant human growth hormone or rhGH, does something fundamentally different. Growth hormone skips the hypothalamus and the pituitary. It just introduces that right into your body. You are injecting the end product, the actual 191 amino acid protein, directly into subcutaneous tissue, and it enters your bloodstream without any involvement from your brain's signaling cascade.

The natural question is whether this would suppress your own production the way that exogenous testosterone suppresses natural testosterone. And the answer, at moderate doses, appears to be no, or at least not in the dramatic way most people assume. The cool thing about doing growth hormone is if I do it, it's actually not going to shut down my natural production. The reason is that growth hormone's primary negative feedback runs through IGF-1, not through growth hormone itself. Your pituitary doesn't have a direct sensor that says "there's too much GH in the blood, stop making it." Instead, it monitors IGF-1 levels, and at moderate physiological doses of exogenous GH, the rise in IGF-1 is not so extreme that it fully silences the pituitary's own pulsatile output.

Research from Veldhuis and colleagues at the Mayo Clinic, published in the Journal of Clinical Endocrinology and Metabolism in 2009, demonstrated something relevant to this. They showed that even when IGF-1 levels are elevated, the dose dependent feedback inhibition of pulsatile growth hormone secretion follows a graded pattern rather than an on off switch. In other words, the pituitary doesn't completely shut down in response to moderate IGF-1 increases, and instead it dials back proportionally to whatever the IGF-1 signal actually demands, which is very different from the hypothalamic pituitary gonadal axis, where introducing exogenous testosterone at almost any supraphysiological dose leads to near complete suppression of LH and FSH, which effectively shuts off testicular production. Growth hormone's feedback system is softer, more like a dimmer than a light switch, at least within the dose ranges typically used for optimization.

The dose ranges that stay within that physiological window are relatively narrow, running from one to two IU per day for women and two to four IU per day for men, and an IU here is an international unit, which for growth hormone corresponds to roughly 0.33 milligrams per IU, so a man taking 3 IU per day is injecting about 1 milligram of growth hormone, which is within the range that clinical protocols use for adult growth hormone deficiency.

At those doses, the downstream effects accumulate steadily over weeks and months rather than appearing overnight. And it's going to have a significant improvement in my recovery, my tissue repair, my muscle growth, my sleep quality, my skin. All of that traces back to the same mechanism because growth hormone stimulates IGF-1 and IGF-1 drives anabolic signaling across virtually every tissue type, so in muscle it promotes satellite cell activation and protein synthesis, in connective tissue it upregulates collagen production which is why people notice improvements in skin elasticity and joint health, and in the brain growth hormone receptors are concentrated in areas that regulate slow wave sleep so raising GH levels often deepens sleep architecture, and deeper sleep in turn triggers more natural GH release, creating a positive cycle.

The recovery piece deserves its own moment because it's often undersold. Growth hormone accelerates the repair of damaged tissue not just by building new protein but by increasing local blood flow through enhanced nitric oxide signaling and by modulating inflammatory cytokines so the body clears damaged cells faster and lays down new extracellular matrix more efficiently. This is why athletes who have used growth hormone often describe the effect not as feeling stronger during a workout but as feeling like they recover from that workout in half the time, because the training itself didn't change but the speed at which the body repairs the damage from that training did.

So the practical question becomes: if direct growth hormone skips the feedback pathway and still doesn't suppress natural production at moderate doses, and if it is, as Josh puts it, arguably the same price as the secretagogues and far more effective, why would anyone choose a secretagogue?

There are a few honest reasons. Secretagogues preserve the pulsatile pattern of release more faithfully, which some clinicians believe matters for long term receptor sensitivity, though the clinical evidence for this being meaningfully different at low doses is limited. Secretagogues also stimulate the full cascade, including some accessory peptides and co-released hormones from the pituitary, which exogenous GH does not. And for people who are younger, with a pituitary that still has plenty of capacity, a secretagogue may be enough to restore youthful output without introducing an exogenous protein at all.

But for someone whose natural production has declined significantly, which is almost everyone over 40 given that GH output drops roughly 14 percent per decade after age 30, a secretagogue is trying to squeeze more output from a system that is already running low on capacity, and direct growth hormone sidesteps that bottleneck entirely by delivering the end product without asking a tired pituitary to manufacture it.

The distinction between these two approaches is really a distinction between augmenting a signal and delivering the product, where one works through your biology and the other works despite it, and the fact that growth hormone can do the latter without triggering the kind of shutdown that testosterone does is what makes it occupy a unique position in the optimization toolbox, a compound that replaces what the body makes less of without punishing it for the help.

References:

Veldhuis JD, Keenan DM, Bailey JN et al.. Testosterone supplementation in older men restrains insulin-like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone secretion. J Clin Endocrinol Metab. 2009. https://pubmed.ncbi.nlm.nih.gov/18984660/